Jim Simons
CAI

Jim Simons’s Caris Life Sciences CAI Stock Holding History

Jim Simons’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.04M Buy
449,900
+120,000
+36% +$2.62M 0.01% 1093
2025
Q4 		$8.9M Buy
329,900
+104,800
+47% +$2.95M 0.01% 978
2025
Q3 		$6.81M Buy
+225,100
New +$7.18M 0.01% 1310

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Jim Simons's CAI Position: Q1 2026 in Review

Jim Simons increased its Caris Life Sciences (CAI) stake by 36% in Q1 2026, buying an estimated $2.62M and bringing the position to 449,900 shares worth $8.04M. The position accounts for 0.01% of the portfolio, ranked #1093.

Jim Simons first reported a position in CAI in Q3 2025 and has held it in 3 quarters since. The position peaked at $8.9M in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Jim Simons held 449,900 shares of Caris Life Sciences worth $8.04M as of Q1 2026.
  • Jim Simons bought 120,000 Caris Life Sciences shares in Q1 2026, an estimated $2.62M.
  • Caris Life Sciences made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1093 holding.
  • Jim Simons first reported a position in Caris Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • Jim Simons's Caris Life Sciences position peaked at $8.9M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.